Endofotonics
Identifying Early-stage Cancers Through In vivo Molecular Diagnosis
Identifying Early-stage Cancers Through In vivo Molecular Diagnosis
Endofotonics is a medtech organisation dedicated to using its proprietary Raman spectroscopy platform technology to improve early cancer detection and reduce cancer burden in patients. Founded in 2013 and headquartered in Singapore with a subsidiary in Shanghai, China, the company developed the SPECTRA IMDx™ system, the world's first real-time in-vivo Raman spectroscopy platform, that improves early gastric cancer detection rate. The company is currently helmed by a lean team of highly skilled and specialized engineers and PhD executives in various fields such as optics, biomedical, academic research, and industrial product development. Endofotonics has received $12 million in Series B funding, led by Beng Teck Liang and Tony Tan Choon Keat in May 29th, 2020. This funding will support the commercialization of the SPECTRA IMDx in the Asia Pacific and beyond. For more information, please visit www.endofotonics.com or email your enquiries to [email protected]. Follow and like them on facebook.com/endofotonics.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $8.50M | 2 | Beng Teck Liang, Tony Tan Choon Keat | 29 May 2020 |
| Series A | Unknown | 2 |
|
01 Jan 2016 |
| Angel Round | $560.00K | - | 01 Apr 2014 |
No recent news or press coverage available for Endofotonics.
We care about your data, and we'd love to use cookies make your experience better.
